Curaxis Pharmaceutical Corp. (ASCH.OB) Issues Optimistic View and Update on Alzheimer Drug Candidate
Curaxis Pharmaceutical Corp. today offered an update on its clinical development plans for Memryte, its candidate to treat mild-to-moderate Alzheimer's disease, noting the economic and medical statistics that drive industry-wide research and development. According to an article from the Alzheimer’s Association, the aggregate cost of care for Alzheimer’s patients in the United States between 2010 and 2050 is forecasted to top $20 trillion dollars. The article also noted that there is no treatment to cure, prevent or delay the progression of Alzheimer’s disease. Patrick Smith, CEO of Curaxis, said the company’s recent merger and status as a publicly traded company…